Operaciones de insiders

EDGAR

Scribe Therapeutics, Inc.

Operaciones informadas por directores, ejecutivos y titulares de más del 10 % en los Formularios 3, 4 y 5 de la SEC, leídas del XML de cada presentación. Los códigos y su redacción son los de la SEC.

El Formulario 4 debe presentarse dentro de los dos días hábiles posteriores a la operación, por lo que las más recientes pueden no estar presentadas aún.

Ventana: operaciones con fecha desde el 18 nov 2025.

Compras en el mercado abierto (código P)
9 operaciones, 4.730.237 acciones
Suma de acciones × precio por acción: 71.344.746,25
Ventas en el mercado abierto (código S)
0 operaciones, — acciones

Los totales suman las operaciones presentadas que se listan; cuentan lo informado y no miden una dirección.

Mostrando 1–35 de 35

Operaciones de insiders, las más recientes primero, según los Formularios 3, 4 y 5 de la SEC
FechaTitular informanteCódigoAdquirido o enajenadoAccionesPrecio por acción, según lo presentadoValor (derivado)Acciones poseídas despuésDirecta o indirectaCasilla de la Regla 10b5-1NotasFuente
28 jul 2026 Presentado el 28 jul 2026Aghazadeh Behzad Director · 10% owner · Other: See RemarksAvoro Capital Advisors LLC Director · 10% owner · Other: See RemarksAvoro Ventures LLC Director · Other: See Remarks
P

Open market or private purchase of non-derivative or derivative security

Common Stock, par value $0.0001 per share
Adquirido (A)790518,25
144.266,25

Derivado: acciones × precio por acción. Valor exacto 144266.25.

3.088.888Indirecta (I) See footnotesNo
F2, F3, F6, F4, F5
  • F2 The shares reported on these lines were purchased on behalf of Avoro Life Sciences in open market transactions on the dates provided in Column 2.
  • F3 Of the 3,088,888 shares reported in Column 5, 2,598,973 shares are held by Avoro Life Sciences and 489,915 shares are held by Avoro Ventures Fund.
  • F6 The amount reported in Column 5 includes 697,650 shares of Common Stock issuable upon conversion of shares of the Issuer's Series B Preferred Stock held by the Funds, which shares were reported on an as-converted basis in the Reporting Persons' Form 3 filed on July 23, 2026. Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-0.1689 basis at the option of the holder and converted automatically into Common Stock, without the payment of any consideration, upon the closing of the IPO on July 27, 2026. No transaction is reported in Table I or Table II with respect to the conversion.
  • F4 The securities reported herein are held directly by Avoro Life Sciences and Avoro Ventures Fund. Avoro Capital Advisors LLC (Avoro Capital Advisors) serves as investment adviser to Avoro Life Sciences, and Avoro Ventures LLC (Avoro Ventures) serves as investment adviser to Avoro Ventures Fund. Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures. By virtue of these relationships, each of the Reporting Persons may be deemed to beneficially own the securities held by the Funds.
  • F5 Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. The shares reported herein are held on behalf of the Funds and other managed accounts, within the meaning of Rule 16a-1(a)(2).
Abrir presentación 0000902664-26-003270 Leído del XML de la presentación Disputar esta fila
27 jul 2026 Presentado el 29 jul 2026AH Bio Fund II, L.P. 10% ownerAH Equity Partners Bio II, L.L.C. 10% ownerAH Bio Fund III, L.P. 10% ownerAH Equity Partners Bio III, L.L.C. 10% ownerAndreessen Marc L 10% ownerHOROWITZ BENJAMIN A 10% owner
C

Conversion of derivative security

Common Stock
Adquirido (A)2.051.742——2.051.742Indirecta (I) By AH Bio Fund II, L.P.No
F1, F2
  • F1 Series A Preferred Stock and Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 5.9218-for-one basis, and had no expiration date.
  • F2 The reported securities are held by AH Bio Fund II, L.P. (AH Bio Fund II), for itself and as nominee for AH Bio Fund II-B, L.P. AH Equity Partners Bio II, L.L.C. (AH EP Bio II) is the general partner of AH Bio Fund II and has sole voting and dispositive power with regard to the securities held by AH Bio Fund II for itself and as nominee. The managing members of AH EP Bio II are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH Bio Fund II for itself and as nominee. Each of the Reporting Persons disclaims the existence of a group and disclaims beneficial ownership of the securities held by AH Bio Fund II for itself and as nominee (and this report shall not be deemed an admission that any such person is the beneficial owner of such securities), except to the extent of such person's pecuniary interest therein, if any.
Abrir presentación 0001231919-26-000813 Leído del XML de la presentación Disputar esta fila
27 jul 2026 Presentado el 29 jul 2026AH Bio Fund II, L.P. 10% ownerAH Equity Partners Bio II, L.L.C. 10% ownerAH Bio Fund III, L.P. 10% ownerAH Equity Partners Bio III, L.L.C. 10% ownerAndreessen Marc L 10% ownerHOROWITZ BENJAMIN A 10% owner
C

Conversion of derivative security

Common Stock
Adquirido (A)697.650——697.650Indirecta (I) By AH Bio Fund III, L.P.No
F1, F3, F4
  • F1 Series A Preferred Stock and Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 5.9218-for-one basis, and had no expiration date.
  • F3 The reported securities are held by AH Bio Fund III, L.P. (AH Bio Fund III), for itself and as nominee for AH Bio Fund III-B, L.P., AH Bio Fund III-Q, L.P. and CLF Partners II, LP. AH Equity Partners Bio III, L.L.C. (AH EP Bio III) is the general partner of AH Bio Fund III and has sole voting and dispositive power with regard to the securities held by AH Bio Fund III for itself and as nominee. The managing members of AH EP Bio III are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH Bio Fund III for itself and as nominee.
  • F4 (Continued from Footnote 3) Each of the Reporting Persons disclaims the existence of a group and disclaims beneficial ownership of the securities held by AH Bio Fund III for itself and as nominee (and this report shall not be deemed an admission that any such person is the beneficial owner of such securities), except to the extent of such person's pecuniary interest therein, if any.
Abrir presentación 0001231919-26-000813 Leído del XML de la presentación Disputar esta fila
27 jul 2026 Presentado el 29 jul 2026AH Bio Fund II, L.P. 10% ownerAH Equity Partners Bio II, L.L.C. 10% ownerAH Bio Fund III, L.P. 10% ownerAH Equity Partners Bio III, L.L.C. 10% ownerAndreessen Marc L 10% ownerHOROWITZ BENJAMIN A 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Adquirido (A)333.33315
4.999.995

Derivado: acciones × precio por acción. Valor exacto 4999995.

2.385.075Indirecta (I) By AH Bio Fund II, L.P.No
F2
  • F2 The reported securities are held by AH Bio Fund II, L.P. (AH Bio Fund II), for itself and as nominee for AH Bio Fund II-B, L.P. AH Equity Partners Bio II, L.L.C. (AH EP Bio II) is the general partner of AH Bio Fund II and has sole voting and dispositive power with regard to the securities held by AH Bio Fund II for itself and as nominee. The managing members of AH EP Bio II are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH Bio Fund II for itself and as nominee. Each of the Reporting Persons disclaims the existence of a group and disclaims beneficial ownership of the securities held by AH Bio Fund II for itself and as nominee (and this report shall not be deemed an admission that any such person is the beneficial owner of such securities), except to the extent of such person's pecuniary interest therein, if any.
Abrir presentación 0001231919-26-000813 Leído del XML de la presentación Disputar esta fila
27 jul 2026 Presentado el 29 jul 2026AH Bio Fund II, L.P. 10% ownerAH Equity Partners Bio II, L.L.C. 10% ownerAH Bio Fund III, L.P. 10% ownerAH Equity Partners Bio III, L.L.C. 10% ownerAndreessen Marc L 10% ownerHOROWITZ BENJAMIN A 10% owner
C

Conversion of derivative security

Valor derivado: Series A Preferred Stock — subyacente Common Stock (2.051.742)
Enajenado (D)12.150.0030—0Indirecta (I) By AH Bio Fund II, L.P.No
F1, F2
  • F1 Series A Preferred Stock and Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 5.9218-for-one basis, and had no expiration date.
  • F2 The reported securities are held by AH Bio Fund II, L.P. (AH Bio Fund II), for itself and as nominee for AH Bio Fund II-B, L.P. AH Equity Partners Bio II, L.L.C. (AH EP Bio II) is the general partner of AH Bio Fund II and has sole voting and dispositive power with regard to the securities held by AH Bio Fund II for itself and as nominee. The managing members of AH EP Bio II are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH Bio Fund II for itself and as nominee. Each of the Reporting Persons disclaims the existence of a group and disclaims beneficial ownership of the securities held by AH Bio Fund II for itself and as nominee (and this report shall not be deemed an admission that any such person is the beneficial owner of such securities), except to the extent of such person's pecuniary interest therein, if any.
Abrir presentación 0001231919-26-000813 Leído del XML de la presentación Disputar esta fila
27 jul 2026 Presentado el 29 jul 2026AH Bio Fund II, L.P. 10% ownerAH Equity Partners Bio II, L.L.C. 10% ownerAH Bio Fund III, L.P. 10% ownerAH Equity Partners Bio III, L.L.C. 10% ownerAndreessen Marc L 10% ownerHOROWITZ BENJAMIN A 10% owner
C

Conversion of derivative security

Valor derivado: Series B Preferred Stock — subyacente Common Stock (697.650)
Enajenado (D)4.131.3440—0Indirecta (I) By AH Bio Fund III, L.P.No
F1, F3, F4
  • F1 Series A Preferred Stock and Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 5.9218-for-one basis, and had no expiration date.
  • F3 The reported securities are held by AH Bio Fund III, L.P. (AH Bio Fund III), for itself and as nominee for AH Bio Fund III-B, L.P., AH Bio Fund III-Q, L.P. and CLF Partners II, LP. AH Equity Partners Bio III, L.L.C. (AH EP Bio III) is the general partner of AH Bio Fund III and has sole voting and dispositive power with regard to the securities held by AH Bio Fund III for itself and as nominee. The managing members of AH EP Bio III are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH Bio Fund III for itself and as nominee.
  • F4 (Continued from Footnote 3) Each of the Reporting Persons disclaims the existence of a group and disclaims beneficial ownership of the securities held by AH Bio Fund III for itself and as nominee (and this report shall not be deemed an admission that any such person is the beneficial owner of such securities), except to the extent of such person's pecuniary interest therein, if any.
Abrir presentación 0001231919-26-000813 Leído del XML de la presentación Disputar esta fila
27 jul 2026 Presentado el 29 jul 2026ORBIMED ADVISORS LLC DirectorOrbiMed Capital GP VIII LLC Director
C

Conversion of derivative security

Common Stock
Adquirido (A)348.825——348.825Indirecta (I) See footnotesNo
F1, F3, F4
  • F1 Each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-0.1689 basis upon the closing of the Issuer's initial public offering on July 27, 2026 without payment of consideration. The Series B Preferred Stock has no expiration date.
  • F3 The shares are held directly by OrbiMed Private Investments VIII, LP (OPI VIII). OrbiMed Capital GP VIII LLC (GP VIII) is the general partner of OPI VIII. OrbiMed Advisors LLC (OrbiMed Advisors) is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
  • F4 This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the Exchange Act), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.
Abrir presentación 0000947871-26-000733 Leído del XML de la presentación Disputar esta fila
27 jul 2026 Presentado el 29 jul 2026ORBIMED ADVISORS LLC DirectorOrbiMed Capital GP VIII LLC Director
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Adquirido (A)1.000.00015
15.000.000

Derivado: acciones × precio por acción. Valor exacto 15000000.

1.348.825Indirecta (I) See footnotesNo
F2, F3, F4
  • F2 Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering.
  • F3 The shares are held directly by OrbiMed Private Investments VIII, LP (OPI VIII). OrbiMed Capital GP VIII LLC (GP VIII) is the general partner of OPI VIII. OrbiMed Advisors LLC (OrbiMed Advisors) is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
  • F4 This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the Exchange Act), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.
Abrir presentación 0000947871-26-000733 Leído del XML de la presentación Disputar esta fila
27 jul 2026 Presentado el 29 jul 2026ORBIMED ADVISORS LLC DirectorOrbiMed Capital GP VIII LLC Director
C

Conversion of derivative security

Valor derivado: Series B Preferred Stock — subyacente Common Stock (348.825)
Enajenado (D)2.065.6720—0Indirecta (I) See footnotesNo
F1, F3, F4
  • F1 Each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-0.1689 basis upon the closing of the Issuer's initial public offering on July 27, 2026 without payment of consideration. The Series B Preferred Stock has no expiration date.
  • F3 The shares are held directly by OrbiMed Private Investments VIII, LP (OPI VIII). OrbiMed Capital GP VIII LLC (GP VIII) is the general partner of OPI VIII. OrbiMed Advisors LLC (OrbiMed Advisors) is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
  • F4 This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the Exchange Act), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.
Abrir presentación 0000947871-26-000733 Leído del XML de la presentación Disputar esta fila
27 jul 2026 Presentado el 29 jul 2026GORDON CARL L Director
C

Conversion of derivative security

Common Stock
Adquirido (A)348.825——348.825Indirecta (I) See footnotesNo
F1, F3, F4
  • F1 Each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-0.1689 basis upon the closing of the Issuer's initial public offering on July 27, 2026 without payment of consideration. The Series B Preferred Stock has no expiration date.
  • F3 The shares are held directly by OrbiMed Private Investments VIII, LP (OPI VIII). OrbiMed Capital GP VIII LLC (GP VIII) is the general partner of OPI VIII. OrbiMed Advisors LLC (OrbiMed Advisors) is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
  • F4 Each of the Reporting Person, OrbiMed Advisors and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the Exchange Act), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Abrir presentación 0000947871-26-000734 Leído del XML de la presentación Disputar esta fila
27 jul 2026 Presentado el 29 jul 2026GORDON CARL L Director
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Adquirido (A)1.000.00015
15.000.000

Derivado: acciones × precio por acción. Valor exacto 15000000.

1.348.825Indirecta (I) See footnotesNo
F2, F3, F4
  • F2 Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering.
  • F3 The shares are held directly by OrbiMed Private Investments VIII, LP (OPI VIII). OrbiMed Capital GP VIII LLC (GP VIII) is the general partner of OPI VIII. OrbiMed Advisors LLC (OrbiMed Advisors) is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
  • F4 Each of the Reporting Person, OrbiMed Advisors and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the Exchange Act), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Abrir presentación 0000947871-26-000734 Leído del XML de la presentación Disputar esta fila
27 jul 2026 Presentado el 29 jul 2026GORDON CARL L Director
C

Conversion of derivative security

Valor derivado: Series B Preferred Stock — subyacente Common Stock (348.825)
Enajenado (D)2.065.6720—0Indirecta (I) See footnotesNo
F1, F3, F4
  • F1 Each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-0.1689 basis upon the closing of the Issuer's initial public offering on July 27, 2026 without payment of consideration. The Series B Preferred Stock has no expiration date.
  • F3 The shares are held directly by OrbiMed Private Investments VIII, LP (OPI VIII). OrbiMed Capital GP VIII LLC (GP VIII) is the general partner of OPI VIII. OrbiMed Advisors LLC (OrbiMed Advisors) is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
  • F4 Each of the Reporting Person, OrbiMed Advisors and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the Exchange Act), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Abrir presentación 0000947871-26-000734 Leído del XML de la presentación Disputar esta fila
27 jul 2026 Presentado el 29 jul 2026Doudna Jennifer A 10% owner
C

Conversion of derivative security

Common Stock
Adquirido (A)12.511——603.547Directa (D) No
F1
  • F1 Each share of Series A-1 Preferred Stock is convertible into Common Stock on a one-for 0.1689 basis at the option of the holder, and will convert automatically upon closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Preferred Stock has no expiration date.
Abrir presentación 0001739090-26-000010 Leído del XML de la presentación Disputar esta fila
27 jul 2026 Presentado el 29 jul 2026Doudna Jennifer A 10% owner
C

Conversion of derivative security

Valor derivado: Series A-1 Preferred Stock — subyacente Common Stock (12.511)
Enajenado (D)74.088——0Directa (D) No
F1
  • F1 Each share of Series A-1 Preferred Stock is convertible into Common Stock on a one-for 0.1689 basis at the option of the holder, and will convert automatically upon closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Preferred Stock has no expiration date.
Abrir presentación 0001739090-26-000010 Leído del XML de la presentación Disputar esta fila
24 jul 2026 Presentado el 28 jul 2026Aghazadeh Behzad Director · 10% owner · Other: See RemarksAvoro Capital Advisors LLC Director · 10% owner · Other: See RemarksAvoro Ventures LLC Director · Other: See Remarks
P

Open market or private purchase of non-derivative or derivative security

Common Stock, par value $0.0001 per share
Adquirido (A)2.333.33315,00
34.999.995

Derivado: acciones × precio por acción. Valor exacto 34999995.00.

3.030.983Indirecta (I) See footnotesNo
F1, F6, F4, F5
  • F1 The shares reported on this line were purchased from underwriters in the Issuer's initial public offering (the IPO) at the initial public offering price of $15.00 per share. Of such shares, 2,066,666 shares were purchased on behalf of Avoro Life Sciences Fund LLC (Avoro Life Sciences) and 266,667 shares were purchased on behalf of Avoro Ventures Fund L.P. (Avoro Ventures Fund and, together with Avoro Life Sciences, the Funds).
  • F6 The amount reported in Column 5 includes 697,650 shares of Common Stock issuable upon conversion of shares of the Issuer's Series B Preferred Stock held by the Funds, which shares were reported on an as-converted basis in the Reporting Persons' Form 3 filed on July 23, 2026. Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-0.1689 basis at the option of the holder and converted automatically into Common Stock, without the payment of any consideration, upon the closing of the IPO on July 27, 2026. No transaction is reported in Table I or Table II with respect to the conversion.
  • F4 The securities reported herein are held directly by Avoro Life Sciences and Avoro Ventures Fund. Avoro Capital Advisors LLC (Avoro Capital Advisors) serves as investment adviser to Avoro Life Sciences, and Avoro Ventures LLC (Avoro Ventures) serves as investment adviser to Avoro Ventures Fund. Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures. By virtue of these relationships, each of the Reporting Persons may be deemed to beneficially own the securities held by the Funds.
  • F5 Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. The shares reported herein are held on behalf of the Funds and other managed accounts, within the meaning of Rule 16a-1(a)(2).
Abrir presentación 0000902664-26-003270 Leído del XML de la presentación Disputar esta fila
24 jul 2026 Presentado el 28 jul 2026Aghazadeh Behzad Director · 10% owner · Other: See RemarksAvoro Capital Advisors LLC Director · 10% owner · Other: See RemarksAvoro Ventures LLC Director · Other: See Remarks
P

Open market or private purchase of non-derivative or derivative security

Common Stock, par value $0.0001 per share
Adquirido (A)50.00022,31
1.115.500

Derivado: acciones × precio por acción. Valor exacto 1115500.00.

3.080.983Indirecta (I) See footnotesNo
F2, F6, F4, F5
  • F2 The shares reported on these lines were purchased on behalf of Avoro Life Sciences in open market transactions on the dates provided in Column 2.
  • F6 The amount reported in Column 5 includes 697,650 shares of Common Stock issuable upon conversion of shares of the Issuer's Series B Preferred Stock held by the Funds, which shares were reported on an as-converted basis in the Reporting Persons' Form 3 filed on July 23, 2026. Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-0.1689 basis at the option of the holder and converted automatically into Common Stock, without the payment of any consideration, upon the closing of the IPO on July 27, 2026. No transaction is reported in Table I or Table II with respect to the conversion.
  • F4 The securities reported herein are held directly by Avoro Life Sciences and Avoro Ventures Fund. Avoro Capital Advisors LLC (Avoro Capital Advisors) serves as investment adviser to Avoro Life Sciences, and Avoro Ventures LLC (Avoro Ventures) serves as investment adviser to Avoro Ventures Fund. Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures. By virtue of these relationships, each of the Reporting Persons may be deemed to beneficially own the securities held by the Funds.
  • F5 Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. The shares reported herein are held on behalf of the Funds and other managed accounts, within the meaning of Rule 16a-1(a)(2).
Abrir presentación 0000902664-26-003270 Leído del XML de la presentación Disputar esta fila
23 jul 2026 Presentado el 28 jul 2026Staahl Brett 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Valor derivado: Stock Option (Right to Buy) — subyacente Common Stock (19.385) — precio de ejercicio 15
Adquirido (A)19.3850—19.385Directa (D) No
F3
  • F3 The options will vest as to 1/48 of the total shares monthly over four years, with the first tranche scheduled to vest on August 23, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Abrir presentación 0002147277-26-000003 Leído del XML de la presentación Disputar esta fila
23 jul 2026 Presentado el 28 jul 2026Staahl Brett 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Valor derivado: Performance-based Stock Option (Right to Buy) — subyacente Common Stock (19.385) — precio de ejercicio 15
Adquirido (A)19.3850—19.385Directa (D) No
F4
  • F4 The options are eligible to vest upon the achievement of certain market-based performance criteria during a performance period beginning on July 23, 2026 and ending on July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Abrir presentación 0002147277-26-000003 Leído del XML de la presentación Disputar esta fila
23 jul 2026 Presentado el 27 jul 2026Lucas Svetlana Officer: Chief Business Officer
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Adquirido (A)300015
45.000

Derivado: acciones × precio por acción. Valor exacto 45000.

3000Indirecta (I) By SpouseNo— Abrir presentación 0001781292-26-000007 Leído del XML de la presentación Disputar esta fila
23 jul 2026 Presentado el 27 jul 2026Lucas Svetlana Officer: Chief Business Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Valor derivado: Stock Option (Right to Buy) — subyacente Common Stock (109.426) — precio de ejercicio 15
Adquirido (A)109.4260—109.426Directa (D) No
F3
  • F3 The options will vest as to 1/48 of the total shares monthly over four years, with the first tranche scheduled to vest on August 23, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Abrir presentación 0001781292-26-000007 Leído del XML de la presentación Disputar esta fila
23 jul 2026 Presentado el 27 jul 2026Lucas Svetlana Officer: Chief Business Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Valor derivado: Performance-based Stock Option (Right to Buy) — subyacente Common Stock (109.426) — precio de ejercicio 15
Adquirido (A)109.4260—109.426Directa (D) No
F4
  • F4 The options are eligible to vest upon the achievement of certain market-based performance criteria during a performance period beginning on July 23, 2026 and ending on July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Abrir presentación 0001781292-26-000007 Leído del XML de la presentación Disputar esta fila
23 jul 2026 Presentado el 27 jul 2026Oakes Benjamin L. Director · Officer: President, CEO · Other: Chairman of the Board
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Valor derivado: Stock Option (Right to Buy) — subyacente Common Stock (264.784) — precio de ejercicio 15
Adquirido (A)264.7840—264.784Directa (D) No
F3
  • F3 The options will vest as to 1/48 of the total shares monthly over four years, with the first tranche scheduled to vest on August 23, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Abrir presentación 0002127814-26-000004 Leído del XML de la presentación Disputar esta fila
23 jul 2026 Presentado el 27 jul 2026Oakes Benjamin L. Director · Officer: President, CEO · Other: Chairman of the Board
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Valor derivado: Performance-based Stock Option (Right to Buy) — subyacente Common Stock (429.599) — precio de ejercicio 15
Adquirido (A)429.5990—429.599Directa (D) No
F4
  • F4 The options are eligible to vest upon the achievement of certain market-based performance criteria during a performance period beginning on July 23, 2026 and ending on July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Abrir presentación 0002127814-26-000004 Leído del XML de la presentación Disputar esta fila
23 jul 2026 Presentado el 27 jul 2026Watson James Dean Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Valor derivado: Stock Option (Right to Buy) — subyacente Common Stock (14.725) — precio de ejercicio 15
Adquirido (A)14.7250—14.725Directa (D) No
F1
  • F1 The options will vest as to 1/3 of the total shares on each of July 23, 2027, July 23, 2028 and July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Abrir presentación 0002130384-26-000004 Leído del XML de la presentación Disputar esta fila
23 jul 2026 Presentado el 27 jul 2026Aghazadeh Behzad Director · Other: See RemarksAvoro Capital Advisors LLC Director · Other: See RemarksAvoro Ventures LLC Director · Other: See Remarks
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Valor derivado: Stock Option (Right to Buy) — subyacente Common Stock (14.725) — precio de ejercicio 15
Adquirido (A)14.7250—14.725Directa (D) No
F1, F2, F3
  • F1 The options will vest as to 1/3 of the total shares on each of July 23, 2027, July 23, 2028 and July 23, 2029, subject to Behzad Aghazadeh's (Dr. Aghazadeh) provision of service to the Issuer on each vesting date.
  • F2 This Form 4 is filed by Dr. Aghazadeh, Avoro Capital Advisors LLC, a Delaware limited liability company (Avoro Capital Advisors), and Avoro Ventures LLC, a Delaware limited liability company (Avoro Ventures, together with Dr. Aghazadeh and Avoro Capital Advisors, the Reporting Persons). Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures LLC.
  • F3 The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.
Abrir presentación 0000902664-26-003254 Leído del XML de la presentación Disputar esta fila
23 jul 2026 Presentado el 27 jul 2026Bleharski Joshua Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Valor derivado: Stock Option (Right to Buy) — subyacente Common Stock (14.725) — precio de ejercicio 15
Adquirido (A)14.7250—14.725Directa (D) No
F1
  • F1 The options will vest as to 1/3 of the total shares on each of July 23, 2027, July 23, 2028 and July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Abrir presentación 0002075052-26-000004 Leído del XML de la presentación Disputar esta fila
23 jul 2026 Presentado el 27 jul 2026GORDON CARL L Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Valor derivado: Stock Option (Right to Buy) — subyacente Common Stock (14.725) — precio de ejercicio 15
Adquirido (A)14.7250—14.725Directa (D) No
F1
  • F1 The options will vest as to 1/3 of the total shares on each of July 23, 2027, July 23, 2028 and July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Abrir presentación 0001282930-26-000004 Leído del XML de la presentación Disputar esta fila
23 jul 2026 Presentado el 27 jul 2026Parrot David Officer: Chief Financial Officer
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Adquirido (A)133315
19.995

Derivado: acciones × precio por acción. Valor exacto 19995.

1333Indirecta (I) By SpouseNo— Abrir presentación 0002127908-26-000004 Leído del XML de la presentación Disputar esta fila
23 jul 2026 Presentado el 27 jul 2026Parrot David Officer: Chief Financial Officer
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Adquirido (A)133315
19.995

Derivado: acciones × precio por acción. Valor exacto 19995.

1333Indirecta (I) By ChildNo— Abrir presentación 0002127908-26-000004 Leído del XML de la presentación Disputar esta fila
23 jul 2026 Presentado el 27 jul 2026Parrot David Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Valor derivado: Stock Option (Right to Buy) — subyacente Common Stock (109.426) — precio de ejercicio 15
Adquirido (A)109.4260—109.426Directa (D) No
F3
  • F3 The options will vest as to 1/48 of the total shares monthly over four years, with the first tranche scheduled to vest on August 23, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Abrir presentación 0002127908-26-000004 Leído del XML de la presentación Disputar esta fila
23 jul 2026 Presentado el 27 jul 2026Parrot David Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Valor derivado: Performance-based Stock Option (Right to Buy) — subyacente Common Stock (109.426) — precio de ejercicio 15
Adquirido (A)109.4260—109.426Directa (D) No
F4
  • F4 The options are eligible to vest upon the achievement of certain market-based performance criteria during a performance period beginning on July 23, 2026 and ending on July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Abrir presentación 0002127908-26-000004 Leído del XML de la presentación Disputar esta fila
13 mar 2026 Presentado el 28 jul 2026Staahl Brett 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Valor derivado: Stock Option (Right to Buy) — subyacente Common Stock (4755) — precio de ejercicio 19.13
Adquirido (A)47550—4755Directa (D) No
F1, F2
  • F1 The transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transaction is reported herein pursuant to Rule 16a-2(a).
  • F2 The option is fully vested.
Abrir presentación 0002147277-26-000003 Leído del XML de la presentación Disputar esta fila
13 mar 2026 Presentado el 27 jul 2026Lucas Svetlana Officer: Chief Business Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Valor derivado: Stock Option (Right to Buy) — subyacente Common Stock (9547) — precio de ejercicio 19.13
Adquirido (A)95470—9547Directa (D) No
F1, F2
  • F1 The transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transaction is reported herein pursuant to Rule 16a-2(a).
  • F2 The option is fully vested.
Abrir presentación 0001781292-26-000007 Leído del XML de la presentación Disputar esta fila
13 mar 2026 Presentado el 27 jul 2026Oakes Benjamin L. Director · Officer: President, CEO · Other: Chairman of the Board
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Valor derivado: Stock Option (Right to Buy) — subyacente Common Stock (12.969) — precio de ejercicio 19.13
Adquirido (A)12.9690—12.969Directa (D) No
F1, F2
  • F1 The transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transaction is reported herein pursuant to Rule 16a-2(a).
  • F2 The option is fully vested.
Abrir presentación 0002127814-26-000004 Leído del XML de la presentación Disputar esta fila
13 mar 2026 Presentado el 27 jul 2026Parrot David Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Valor derivado: Stock Option (Right to Buy) — subyacente Common Stock (8909) — precio de ejercicio 19.13
Adquirido (A)89090—8909Directa (D) No
F1, F2
  • F1 The transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transaction is reported herein pursuant to Rule 16a-2(a).
  • F2 The option is fully vested.
Abrir presentación 0002127908-26-000004 Leído del XML de la presentación Disputar esta fila

Titulares institucionales (Formulario 13F)

Trimestre terminado el 2026-09-30: 8793 presentaciones leídas, la última del 17 nov 2026. Trimestre anterior terminado el 2026-06-30: 9164 presentaciones leídas.

Mostrando 1–50 de 62

Titulares institucionales, la posición mayor primero, según lo presentado
GestorAcciones o principalValor según lo presentadoDiferencia con el trimestre anteriorFuente
a16z Capital Management, L.L.C. 3.082.725 SH56.737.554 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0001540358-26-000014 Presentado el 16 nov 2026 Disputar esta fila
Avoro Capital Advisors LLC 2.598.973 SH47.834.098 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0001104659-26-127608 Presentado el 16 nov 2026 Disputar esta fila
RA CAPITAL MANAGEMENT, L.P. 1.802.178 SH33.169.086 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0001104659-26-128411 Presentado el 16 nov 2026 Disputar esta fila
ORBIMED ADVISORS LLC 1.348.825 SH24.825.124 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0001172661-26-005349 Presentado el 16 nov 2026 Disputar esta fila
PERCEPTIVE ADVISORS LLC 920.341 SH16.938.876 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0001012975-26-001063 Presentado el 16 nov 2026 Disputar esta fila
ARK Investment Management LLC 786.921 SH14.483.278 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0001104659-26-126785 Presentado el 13 nov 2026 Disputar esta fila
BAKER BROS. ADVISORS LP 688.691 SH12.675.358 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0001104659-26-128308 Presentado el 16 nov 2026 Disputar esta fila
PRICE T ROWE ASSOCIATES INC /MD/ Informado en parte bajo otro gestor684.706 SH12.603 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0000080255-26-000736 Presentado el 16 nov 2026 Disputar esta fila
BlackRock, Inc. Informado en parte bajo otro gestor679.786 SH12.511.461 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0002012383-26-003985 Presentado el 13 nov 2026 Disputar esta fila
Sanofi 500.000 SH9.202.500 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0001193125-26-448717 Presentado el 5 nov 2026 Disputar esta fila
VANGUARD CAPITAL MANAGEMENT LLC 407.630 SH7.502.430 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0002100119-26-001711 Presentado el 13 nov 2026 Disputar esta fila
FRANKLIN TEMPLETON INC Informado en parte bajo otro gestor380.019 SH6.376.719 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0000038777-26-000291 Presentado el 12 nov 2026 Disputar esta fila
ADAGE CAPITAL PARTNERS GP, L.L.C. 380.000 SH6.993.900 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0001172661-26-005200 Presentado el 16 nov 2026 Disputar esta fila
FARALLON CAPITAL MANAGEMENT, L.L.C. 380.000 SH6.993.900 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0000908834-26-000540 Presentado el 16 nov 2026 Disputar esta fila
GEODE CAPITAL MANAGEMENT, LLC Informado en parte bajo otro gestor245.412 SH4.518.022 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0001214717-26-000012 Presentado el 6 nov 2026 Disputar esta fila
STATE STREET CORP Informado en parte bajo otro gestor171.147 SH3.149.961 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0000093751-26-000747 Presentado el 12 nov 2026 Disputar esta fila
Alyeska Investment Group, L.P. 150.000 SH2.760.750 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0001172661-26-005329 Presentado el 16 nov 2026 Disputar esta fila
Menlo Ventures Management, L.P. 97.690 SH1.797.984 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0001911541-26-000014 Presentado el 6 nov 2026 Disputar esta fila
TD ASSET MANAGEMENT INC 83.342 SH1.919.366 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0001193125-26-460060 Presentado el 13 nov 2026 Disputar esta fila
Amova Asset Management Americas, Inc. Informado en parte bajo otro gestor74.910 SH1.378.344 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0001140361-26-043552 Presentado el 13 nov 2026 Disputar esta fila
Sumitomo Mitsui Trust Group, Inc. Informado en parte bajo otro gestor74.910 SH1.378.719 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0001214659-26-013361 Presentado el 29 oct 2026 Disputar esta fila
NORTHERN TRUST CORP Informado en parte bajo otro gestor74.721 SH1.375.240 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0000073124-26-000067 Presentado el 16 nov 2026 Disputar esta fila
UBS Group AG Informado en parte bajo otro gestor71.067 SH1.307.988 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0001610520-26-000121 Presentado el 10 nov 2026 Disputar esta fila
VANGUARD PORTFOLIO MANAGEMENT LLC 67.039 SH1.233.853 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0002100121-26-001150 Presentado el 13 nov 2026 Disputar esta fila
VANGUARD FIDUCIARY TRUST CO 64.267 SH1.182.834 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0000933478-26-000017 Presentado el 13 nov 2026 Disputar esta fila
Nuveen, LLC Informado en parte bajo otro gestor41.470 SH763.255 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0000930413-26-003284 Presentado el 10 nov 2026 Disputar esta fila
IQ EQ FUND MANAGEMENT (IRELAND) Ltd 40.876 SH0 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0001213900-26-119414 Presentado el 13 nov 2026 Disputar esta fila
Longaeva Partners L.P. Informado en parte bajo otro gestor34.034 SH626.396 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0001193125-26-463222 Presentado el 16 nov 2026 Disputar esta fila
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 31.644 SH582.408 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0000884546-26-000417 Presentado el 16 nov 2026 Disputar esta fila
BANK OF AMERICA CORP /DE/ Informado en parte bajo otro gestor27.589 SH507.776 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0000070858-26-000589 Presentado el 16 nov 2026 Disputar esta fila
Point72 Asset Management, L.P. 22.771 SH419.100 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0000919574-26-008126 Presentado el 16 nov 2026 Disputar esta fila
WELLS FARGO COMPANY/MN Informado en parte bajo otro gestor22.500 SH414.112 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0000072971-26-000342 Presentado el 16 nov 2026 Disputar esta fila
GOLDMAN SACHS GROUP INC Informado en parte bajo otro gestor21.635 SH398.192 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0000886982-26-000647 Presentado el 16 nov 2026 Disputar esta fila
Bank of New York Mellon Corp Informado en parte bajo otro gestor20.396 SH375.389 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0001390777-26-000121 Presentado el 5 nov 2026 Disputar esta fila
Focus Partners Wealth 20.025 SH368.560 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0001542153-26-000021 Presentado el 12 nov 2026 Disputar esta fila
SUSQUEHANNA INTERNATIONAL GROUP, LLP Informado en parte bajo otro gestor13.641 SH251.063 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0001446194-26-000009 Presentado el 16 nov 2026 Disputar esta fila
SEVEN GRAND MANAGERS, LLC 10.000 SH184.050 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0001420506-26-002775 Presentado el 16 nov 2026 Disputar esta fila
RHUMBLINE ADVISERS 8897 SH163.742 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0001115418-26-000015 Presentado el 10 nov 2026 Disputar esta fila
MORGAN STANLEY Informado en parte bajo otro gestor8536 SH157.106 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0000895421-26-000309 Presentado el 13 nov 2026 Disputar esta fila
DEUTSCHE BANK AG\ Informado en parte bajo otro gestor8269 SH152.233 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0000948046-26-000083 Presentado el 6 nov 2026 Disputar esta fila
JPMORGAN CHASE CO Informado en parte bajo otro gestor6028 SH138.825 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0000019617-26-000404 Presentado el 12 nov 2026 Disputar esta fila
MetLife Investment Management, LLC Informado en parte bajo otro gestor5814 SH107.007 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0001628280-26-073956 Presentado el 16 nov 2026 Disputar esta fila
CITIGROUP INC Informado en parte bajo otro gestor4742 SH87.277 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0000831001-26-000052 Presentado el 4 nov 2026 Disputar esta fila
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Informado en parte bajo otro gestor4636 SH85.326 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0000905148-26-004850 Presentado el 16 nov 2026 Disputar esta fila
KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC 4195 SH77.209 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0001398344-26-020056 Presentado el 13 nov 2026 Disputar esta fila
Vanguard Global Advisers, LLC 3592 SH66.111 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0001811242-26-000017 Presentado el 13 nov 2026 Disputar esta fila
TEMA ETFS LLC 3046 SH56.062 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0001829126-26-011223 Presentado el 16 oct 2026 Disputar esta fila
STRS OHIO 2600 SH47.853 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0000820478-26-000018 Presentado el 30 oct 2026 Disputar esta fila
BNP PARIBAS FINANCIAL MARKETS Informado en parte bajo otro gestor2400 SH44.172 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0001166588-26-000012 Presentado el 12 nov 2026 Disputar esta fila
Police Firemen's Retirement System of New Jersey Informado en parte bajo otro gestor2289 SH42.129 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0002040686-26-000007 Presentado el 9 nov 2026 Disputar esta fila
  • El Formulario 13F cubre solo posiciones largas en valores de la Sección 13(f): ni posiciones cortas ni valores fuera de esa lista.
  • Un gestor que aún no ha presentado el último trimestre está ausente, no en cero; las presentaciones vencen hasta 45 días después del cierre del trimestre.
  • Una diferencia es la que hay entre dos instantáneas de cierre de trimestre, no una operación.
  • Una posición informada bajo otro gestor puede aparecer también en la presentación de ese gestor; las filas no se suman.
  • No se muestran las posiciones que la lista de valores no puede atribuir a esta empresa o atribuye de forma ambigua.

Titulares del 5 % (Anexos 13D y 13G)

Aquí se leen los anexos presentados en el formato estructurado de la SEC (desde finales de 2024). Los anteriores son texto libre y no se leen.

Titulares del 5 %, el evento más reciente primero, según lo presentado
TitularPorcentaje de la claseAcciones en poderFecha del eventoFormularioFuente
AH Bio Fund II, L.P. Common Stock, $0.001 par value per share12.62.385.075,0009/30/2026 Presentado el 16 nov 2026SCHEDULE 13GAbrir presentación 0001725721-26-000009 Disputar esta fila
AH Equity Partners Bio II, L.L.C. Common Stock, $0.001 par value per share12.62.385.075,0009/30/2026 Presentado el 16 nov 2026SCHEDULE 13GAbrir presentación 0001725721-26-000009 Disputar esta fila
AH Bio Fund III, L.P. Common Stock, $0.001 par value per share3.7697.650,0009/30/2026 Presentado el 16 nov 2026SCHEDULE 13GAbrir presentación 0001725721-26-000009 Disputar esta fila
AH Equity Partners Bio III, L.L.C. Common Stock, $0.001 par value per share3.7697.650,0009/30/2026 Presentado el 16 nov 2026SCHEDULE 13GAbrir presentación 0001725721-26-000009 Disputar esta fila
Marc L. Andreessen Common Stock, $0.001 par value per share16.33.082.725,0009/30/2026 Presentado el 16 nov 2026SCHEDULE 13GAbrir presentación 0001725721-26-000009 Disputar esta fila
Benjamin A. Horowitz Common Stock, $0.001 par value per share16.33.082.725,0009/30/2026 Presentado el 16 nov 2026SCHEDULE 13GAbrir presentación 0001725721-26-000009 Disputar esta fila
RA Capital Management, L.P. Common Stock, $0.001 par value per share9.61.802.178,0007/27/2026 Presentado el 3 ago 2026SCHEDULE 13GAbrir presentación 0001346824-26-000210 Disputar esta fila
Peter Kolchinsky Common Stock, $0.001 par value per share9.61.802.178,0007/27/2026 Presentado el 3 ago 2026SCHEDULE 13GAbrir presentación 0001346824-26-000210 Disputar esta fila
Rajeev Shah Common Stock, $0.001 par value per share9.61.802.178,0007/27/2026 Presentado el 3 ago 2026SCHEDULE 13GAbrir presentación 0001346824-26-000210 Disputar esta fila
RA Capital Healthcare Fund, L.P. Common Stock, $0.001 par value per share9.11.714.582,0007/27/2026 Presentado el 3 ago 2026SCHEDULE 13GAbrir presentación 0001346824-26-000210 Disputar esta fila
ORBIMED ADVISORS LLC Common Stock7.21.348.825,0007/27/2026 Presentado el 29 jul 2026SCHEDULE 13DAbrir presentación 0000947871-26-000732 Disputar esta fila
ORBIMED CAPITAL GP VIII LLC Common Stock7.21.348.825,0007/27/2026 Presentado el 29 jul 2026SCHEDULE 13DAbrir presentación 0000947871-26-000732 Disputar esta fila
Avoro Capital Advisors LLC Common Stock, $0.001 par value per share13.782.598.973,0007/24/2026 Presentado el 30 jul 2026SCHEDULE 13DAbrir presentación 0000902664-26-003281 Disputar esta fila
Avoro Ventures LLC Common Stock, $0.001 par value per share2.60489.915,0007/24/2026 Presentado el 30 jul 2026SCHEDULE 13DAbrir presentación 0000902664-26-003281 Disputar esta fila
Aghazadeh Behzad Common Stock, $0.001 par value per share16.373.088.888,0007/24/2026 Presentado el 30 jul 2026SCHEDULE 13DAbrir presentación 0000902664-26-003281 Disputar esta fila
ELI LILLY Co Common stock, $0.001 par value per share7.31.388.161,0007/23/2026 Presentado el 30 jul 2026SCHEDULE 13DAbrir presentación 0000059478-26-000072 Disputar esta fila

El porcentaje es de la clase que indica la presentación, según lo declaró el titular. Los miembros de un grupo informan cada uno las acciones del grupo, por lo que las filas no se suman.

Qué se leyó

2.241.208 presentaciones leídas, del 14 jun 2004 al 17 nov 2026: Formularios 3, 3/A, 4, 4/A, 5, 5/A.

Algunos años pueden estar incompletos mientras se sigue leyendo el archivo. Un año con pocas presentaciones aquí no afirma que se hicieran pocas.

Presentaciones leídas, por año de presentación
Año de presentaciónPresentaciones leídas
20151
2016204.322
2017202.494
2018202.048
2019193.638
2020144.184
2021224.474
2022158.941
2023199.811
2024209.823
2025235.520
2026260.174

Las presentaciones anteriores a que la SEC exigiera XML se listan, pero no se extraen.

Volver a Scribe Therapeutics, Inc.